(Q30756778)

26 June 2017

1 reference

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data (English)

1 reference

26 June 2017

1 reference

1 reference

Alessandra Larocca

7

0 references

Massimo Offidani

Massimo Offidani

10

0 references

Giovannino Ciccone

Giovannino Ciccone

21

0 references

Michele Cavo

Michele Cavo

18

0 references

Pellegrino Musto

Pellegrino Musto

9

0 references

Athanasios Dimopoulos

Meletios A Dimopoulos

16

0 references

Roman Hajek

Roman Hajek

17

0 references

Bart Barlogie

24

Bart Barlogie

1 reference

26 June 2017

20

Sagar Lonial

1 reference

26 June 2017

23

Kenneth Anderson

1 reference

26 June 2017

25

Pieter Sonneveld

1 reference

26 June 2017

19

Paul Richardson

1 reference

26 June 2017

1

Antonio Palumbo

1 reference

26 June 2017

13

Sonja Zweegman

1 reference

26 June 2017

8

Bronno van der Holt

1 reference

26 June 2017

3

Shaji K Kumar

1 reference

26 June 2017

22

Mario Boccadoro

1 reference

26 June 2017

2

Sara Bringhen

1 reference

26 June 2017

Maria Teresa Petrucci

11

Maria T Petrucci

1 reference

Débora Andréa Evangelista Façanha

26 June 2017

12

Andrea Evangelista

1 reference

26 June 2017

26

Philip L McCarthy

1 reference

26 June 2017

5

Saad Usmani

1 reference

26 June 2017

14

Ajay K Nooka

1 reference

26 June 2017

Giulia Lupparelli

4

1 reference

26 June 2017

Anders Waage

6

1 reference

26 June 2017

Andrew Spencer

15

1 reference

26 June 2017

publication date

11 February 2014

1 reference

Lancet Oncology Commission

26 June 2017

published in

1 reference

26 June 2017

volume

15

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

333-342

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

1 reference

7 January 2021

Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Second malignancies after multiple myeloma: from 1960s to 2010s

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Competing risks regression for clustered data.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Melphalan may be a more potent leukemogen than cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970609-0

7 January 2021

10.1016/S1470-2045(13)70609-0

Identifiers

DOI

1 reference

26 June 2017

1 reference